ValuEngine cut shares of Gilead Sciences (NASDAQ:GILD) from a strong-buy rating to a buy rating in a research note released on Wednesday, May 2nd.
A number of other research firms have also commented on GILD. Zacks Investment Research lowered Gilead Sciences from a hold rating to a sell rating in a research report on Wednesday, April 11th. Citigroup raised Gilead Sciences from a neutral rating to a buy rating and lowered their price target for the company from $88.80 to $76.00 in a research report on Tuesday, January 30th. Royal Bank of Canada reissued a buy rating and issued a $94.00 price target on shares of Gilead Sciences in a research report on Friday, February 23rd. BMO Capital Markets increased their price target on Gilead Sciences from $86.00 to $88.00 and gave the company a market perform rating in a research report on Thursday, February 8th. Finally, Vetr lowered Gilead Sciences from a strong-buy rating to a buy rating and set a $90.00 target price for the company. in a research report on Wednesday, January 17th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Gilead Sciences presently has an average rating of Buy and a consensus price target of $88.14.
Gilead Sciences traded up $0.56, reaching $67.55, on Wednesday, according to MarketBeat Ratings. The company had a trading volume of 6,176,574 shares, compared to its average volume of 8,200,159. The firm has a market capitalization of $87.18 billion, a P/E ratio of 7.89, a PEG ratio of -5.83 and a beta of 1.19. Gilead Sciences has a 52-week low of $67.01 and a 52-week high of $67.62. The company has a current ratio of 2.84, a quick ratio of 2.75 and a debt-to-equity ratio of 1.32.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 28th. Investors of record on Friday, June 15th will be issued a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 3.38%. The ex-dividend date of this dividend is Thursday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 26.64%.
In other Gilead Sciences news, Chairman John C. Martin sold 50,000 shares of the firm’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $78.65, for a total value of $3,932,500.00. Following the completion of the transaction, the chairman now owns 3,067,762 shares in the company, valued at approximately $241,279,481.30. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Robin L. Washington sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total value of $401,550.00. Following the completion of the transaction, the chief financial officer now owns 23,749 shares of the company’s stock, valued at approximately $1,907,282.19. The disclosure for this sale can be found here. In the last three months, insiders sold 241,102 shares of company stock valued at $18,237,884. 1.16% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. boosted its position in shares of Gilead Sciences by 1.4% during the 1st quarter. BlackRock Inc. now owns 105,236,053 shares of the biopharmaceutical company’s stock valued at $7,933,746,000 after acquiring an additional 1,438,806 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Gilead Sciences by 1.5% during the 4th quarter. Bank of New York Mellon Corp now owns 30,542,928 shares of the biopharmaceutical company’s stock valued at $2,188,095,000 after acquiring an additional 446,263 shares during the last quarter. Parnassus Investments CA boosted its position in shares of Gilead Sciences by 2.5% during the 4th quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock valued at $1,372,604,000 after acquiring an additional 464,609 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Gilead Sciences by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 15,849,063 shares of the biopharmaceutical company’s stock valued at $1,133,346,000 after acquiring an additional 379,867 shares during the last quarter. Finally, Capital International Investors boosted its position in shares of Gilead Sciences by 86.6% during the 3rd quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock valued at $908,803,000 after acquiring an additional 5,205,983 shares during the last quarter. Institutional investors and hedge funds own 78.16% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.